While life sciences M&A activity surges in today’s markets, the shift in regulatory enforcement priorities, constant innovation in technology, and strategic growth opportunities are changing the way dealmakers are approaching...more
Whether you’re just starting up or you’re well-established and attracting offers, if selling is your goal, there’s no better time than now to start planning your exit strategy. Drawing on experience and insights amassed...more
It’s no secret that Democrats are traditionally trustbusters, but the Biden Administration is taking things to a whole new level, bringing novel—and arguably weak—cases that nonetheless slow or block tie-ups among healthcare...more
12/13/2023
/ Acquisitions ,
Antitrust Division ,
Biden Administration ,
Competition ,
Enforcement ,
Federal Trade Commission (FTC) ,
Healthcare ,
Healthcare Facilities ,
Hospitals ,
Medical Devices ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Agenda ,
Regulatory Reform
On May 1, 2023, the U.S. Court of Appeals for the Seventh Circuit affirmed the dismissal of a putative class action alleging violations of the Illinois Genetic Information Privacy Act (GIPA) against the asset management firm...more
In the first case following Akorn v. Fresenius to rule on a party’s entitlement to terminate a merger agreement on the basis of a material adverse effect (MAE), the Delaware Court of Chancery ordered Boston Scientific...more
12/24/2019
/ Acquisitions ,
Breach of Contract ,
Contract Termination ,
Due Diligence ,
Food and Drug Administration (FDA) ,
Material Adverse Effects ,
Merger Agreements ,
Mergers ,
Pharmaceutical Industry ,
Popular ,
Remedies